Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.820
Open
7.460
VWAP
7.56
Vol
1.07M
Mkt Cap
298.68M
Low
7.345
Amount
8.06M
EV/EBITDA(TTM)
--
Total Shares
39.25M
EV
69.48M
EV/OCF(TTM)
--
P/S(TTM)
1.97
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
28.29M
-29.66%
--
--
26.05M
-26.25%
--
--
33.60M
-3.69%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for RxSight, Inc. (RXST) for FY2025, with the revenue forecasts being adjusted by -21.54% over the past three months. During the same period, the stock price has changed by -48.24%.
Revenue Estimates for FY2025
Revise Downward
-21.54%
In Past 3 Month
Stock Price
Go Down
-48.24%
In Past 3 Month
7 Analyst Rating
172.38% Upside
Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 20.02 USD with a low forecast of 13.14 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
1 Sell
Moderate Buy
172.38% Upside
Current: 7.350
Low
13.14
Averages
20.02
High
28.00
172.38% Upside
Current: 7.350
Low
13.14
Averages
20.02
High
28.00
Morgan Stanley
Overweight -> Equal Weight
downgrade
$20 -> $9
2025-07-15
Reason
Morgan Stanley
Price Target
$20 -> $9
2025-07-15
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded RxSight to Equal Weight from Overweight with a price target of $9, down from $20. Morgan Stanley says it doesn't have visibility on RxSight's near-term growth to remain Overweight following the significant slowdown in LDD placements in Q2 as well as a tougher competitive environment, the analyst tells investors in a research note.
Jefferies
Buy
to
Hold
downgrade
$24 -> $9
2025-07-10
Reason
Jefferies
Price Target
$24 -> $9
2025-07-10
downgrade
Buy
to
Hold
Reason
Jefferies downgraded RxSight to Hold from Buy with a price target of $9, down from $24. The company reported a second consecutive quarter of "missing and lowering," as the capital selling cycle has elongated, new customers are slower to ramp, and existing customer utilizations have flattened, the analyst tells investors in a research note. The firm says that while RxSight has initiated a new commercial pivot to improve utilization and growth, it is uncertain about the pace of the company's growth recovery as well as timing of an inflection.
Wells Fargo
Overweight -> Equal Weight
downgrade
$25 -> $9
2025-07-09
Reason
Wells Fargo
Price Target
$25 -> $9
2025-07-09
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded RxSight to Equal Weight from Overweight with a price target of $9, down from $25. The firm admits to misjudging RxSight's structural issues after the company reported "another disappointing quarter." RxSight's Q2 missed Street estimates by 16% as light adjustable lens trends deteriorated through the quarter, the analyst tells investors in a research note. Wells is now uncertain about the company's future performance.
BTIG
Ryan Zimmerman
Buy -> Neutral
downgrade
2025-07-09
Reason
BTIG
Ryan Zimmerman
Price Target
2025-07-09
downgrade
Buy -> Neutral
Reason
BTIG analyst Ryan Zimmerman downgraded RxSight to Neutral from Buy without a price target. The firm cites the "another quarter of weak" of preliminary results due to declining utilization and "extremely soft" Light Delivery Device sales for the downgrade. RxSight's inability to navigate challenges along with a the need to readjust its sales processes suggests a drawn-out recovery, the analyst tells investors in a research note.
Stifel
Hold
downgrade
$17 -> $9
2025-07-09
Reason
Stifel
Price Target
$17 -> $9
2025-07-09
downgrade
Hold
Reason
Stifel lowered the firm's price target on RxSight to $9 from $17 and keeps a Hold rating on the shares. The firm's Light Adjustable Lens consignment inventory analysis shows normal customer inventory levels at the end of 1Q25, despite unexpected March LAL softness, the analyst tells investors in a research note.
Outperform -> Perform
downgrade
2025-07-09
Reason
Price Target
2025-07-09
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded RxSight to Perform from Outperform.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Rxsight Inc (RXST.O) is -6.48, compared to its 5-year average forward P/E of -29.53. For a more detailed relative valuation and DCF analysis to assess Rxsight Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-29.53
Current PE
-6.48
Overvalued PE
-0.17
Undervalued PE
-58.89
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-29.31
Current EV/EBITDA
-1.89
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-59.40
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
8.67
Current PS
2.43
Overvalued PS
12.01
Undervalued PS
5.34
Financials
Annual
Quarterly
FY2025Q1
YoY :
+28.41%
37.90M
Total Revenue
FY2025Q1
YoY :
+0.04%
-10.67M
Operating Profit
FY2025Q1
YoY :
-10.00%
-8.19M
Net Income after Tax
FY2025Q1
YoY :
-20.00%
-0.20
EPS - Diluted
FY2025Q1
YoY :
-16.58%
-9.41M
Free Cash Flow
FY2025Q1
YoY :
+6.66%
74.76
Gross Profit Margin - %
FY2025Q1
YoY :
-64.31%
-13.83
FCF Margin - %
FY2025Q1
YoY :
-29.91%
-21.61
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
180.0K
USD
1
6-9
Months
1.3M
USD
9
0-12
Months
3.2M
USD
17
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
5
1.1M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
173.8K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
100.0K
Volume
Months
6-9
3
65.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
180.0K
USD
1
6-9
Months
1.3M
USD
9
0-12
Months
3.2M
USD
17
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
5
1.1M
USD
Months
0-12
0
0.0
USD
Months
RXST News & Events
Events Timeline
2025-07-08 (ET)
2025-07-08
16:26:53
RxSight cuts FY25 revenue view to $120M-$130M from $160M-$175M
2025-07-08
16:24:37
RxSight sees Q2 revenue $33.6M, consensus $39.78M
2025-05-07 (ET)
2025-05-07
16:19:16
RxSight backs FY25 revenue view $160M-$175M, consensus $170.34M
Sign Up For More Events
Sign Up For More Events
News
7.0
07-21NewsfilterRxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RXST
7.0
07-19GlobenewswireRXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company
7.0
07-18GlobenewswireRXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud Investigation – Contact BFA Law if You Lost Money
Sign Up For More News
People Also Watch
AMWD
American Woodmark Corp
52.290
USD
-0.31%
NMFC
New Mountain Finance Corp
10.580
USD
-1.12%
DEA
Easterly Government Properties Inc
22.880
USD
+1.24%
SYRE
Spyre Therapeutics Inc
16.350
USD
+0.37%
APOG
Apogee Enterprises Inc
41.540
USD
-1.02%
CBRL
Cracker Barrel Old Country Store Inc
66.560
USD
+1.40%
SPRY
ARS Pharmaceuticals Inc
17.850
USD
-0.39%
IDT
IDT Corp
57.510
USD
+2.13%
IMAX
Imax Corp
28.800
USD
+1.34%
SAFE
Safehold Inc
14.720
USD
-0.07%
FAQ
What is Rxsight Inc (RXST) stock price today?
The current price of RXST is 7.35 USD — it has increased 0 % in the last trading day.
What is Rxsight Inc (RXST)'s business?
What is the price predicton of RXST Stock?
What is Rxsight Inc (RXST)'s revenue for the last quarter?
What is Rxsight Inc (RXST)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Rxsight Inc (RXST)'s fundamentals?
How many employees does Rxsight Inc (RXST). have?